The Journal of Urology
Volume 180, Issue 6 , Pages 2299-2300 , December 2008

Are We Overtreating Prostate Cancer?

  • Judd W. Moul

      Affiliations

    • Financial interest and/or other relationship with AstraZeneca and Sanofi Aventis.

References 

  1. Wu H, Sun L, Moul JW, Wu HY, McLeod DG, Amling C, et al. Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol. 2004;171:1111
  2. Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21:4001

PII: S0022-5347(08)02587-1

doi: 10.1016/j.juro.2008.09.067

The Journal of Urology
Volume 180, Issue 6 , Pages 2299-2300 , December 2008

Article Tools